In this study, a new precursor was synthesized form the reaction of melamine and chloroacetonitrile. By using this pre‐material, the new mesoporous triazine based‐carbon material was prepared during ionothermal process with the help of ZnCl2, and used as the excellent support for silver nano‐particles. The new nano‐catalyst was named Ag/mCTF(mesoporous Carbon Triazine Framework), and fully characterized by various analytical methods including Fourier transformed infrared spectroscopy (FT‐IR), field emission scanning electron microscopy (FE‐SEM), energy‐dispersive X‐ray spectroscopy (EDX), X‐ray diffraction (XRD) and thermogravimetric analysis (TGA). The catalyst ability of Ag/mCTF was survived in the reduction reaction of nitroaromatic compounds. The results show that this new catalyst produced anilines in good yields in benign condition. The other merit of this heterogeneous catalyst was high recyclability without significant decrease in its performance.

Background: Multiple sclerosis (MS) is an autoimmune disease that causes chronic inflammation of the central nervous system. MicroRNAs (miRNAs) are small non-coding RNAs 19-24 nucleotides long, which are differentially expressed in different tissues. The role of miRNAs in MS remains unclear. We assessed miR-10a transcript levels in MS patients during recurrence and two months after relapse. Materials and Methods:In this case-control study, we used real-time PCR to examine miR-10a expression in the peripheral blood mononuclear cells of 60 patients with relapsing-remitting multiple sclerosis (RRMS), 30 during recurrence and 30 two months after relapse, and 30 healthy subjects who were referred to the MS Clinic of Kashani Hospital, Isfahan Province. In silico analysis was also performed on the validated miR-10a targets using miRTarBase. Results: miR-10a expression was higher in RRMS patients during recurrence and two months after relapse (p < 0.0001 and p < 0.0001, respectively) than in the healthy subjects. Furthermore, in silico molecular signaling enrichment analysis identified 12 mRNAs as validated miR-10a targets. Conclusion: The expression of miR-10a was elevated in patients with RRMS compared to healthy subjects, suggesting that miR-10a could be a potential biomarker for RRMS diagnosis.